ストックスクリーナーアプリを入手
86.58
3.58%
2.99
アフターアワーズ：
87.02
0.44
+0.51%
前日終値:
$83.59
開ける：
$85
24時間の取引高:
2.15M
Relative Volume:
1.12
時価総額：
$11.36B
収益：
$982.02M
当期純損益:
$-416.28M
株価収益率:
-26.12
EPS:
-3.3148
ネットキャッシュフロー:
$-233.07M
1週間 パフォーマンス:
-0.79%
1か月 パフォーマンス:
-9.12%
6か月 パフォーマンス:
+43.87%
1年 パフォーマンス:
+86.35%
1日の値動き範囲:
$84.51
$89.26
1週間の範囲:
$82.39
$90.28
52週間の値動き範囲:
$36.36
$120.74
Guardant Health Inc Stock (GH) Company Profile
Compare GH vs TMO, DHR, IDXX, A, WAT
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
86.58 | 10.96B | 982.02M | -416.28M | -233.07M | -3.3148 |
TMO
Thermo Fisher Scientific Inc
|
490.77 | 182.14B | 44.56B | 6.72B | 6.29B | 17.74 |
DHR
Danaher Corp
|
187.15 | 134.43B | 24.57B | 3.60B | 5.26B | 5.051 |
IDXX
Idexx Laboratories Inc
|
575.72 | 45.40B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
112.98 | 32.27B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
302.32 | 29.62B | 3.17B | 642.63M | 516.49M | 10.77 |
Guardant Health Inc Stock (GH) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-20 | 繰り返されました | Canaccord Genuity | Buy |
| 2026-02-17 | 開始されました | Robert W. Baird | Outperform |
| 2026-01-05 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2025-12-02 | 再開されました | Morgan Stanley | Overweight |
| 2025-09-25 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2025-09-22 | 再開されました | Wells Fargo | Overweight |
| 2025-04-10 | 開始されました | Mizuho | Outperform |
| 2025-01-23 | 開始されました | Barclays | Overweight |
| 2024-06-28 | アップグレード | Guggenheim | Neutral → Buy |
| 2024-06-03 | 再開されました | Jefferies | Buy |
| 2024-04-24 | 再開されました | Craig Hallum | Buy |
| 2023-12-14 | 開始されました | Guggenheim | Neutral |
| 2023-12-13 | 開始されました | Wolfe Research | Peer Perform |
| 2023-11-13 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2023-09-28 | 開始されました | Bernstein | Outperform |
| 2023-09-27 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2023-07-05 | 再開されました | JP Morgan | Overweight |
| 2023-05-26 | アップグレード | Citigroup | Neutral → Buy |
| 2023-05-05 | 開始されました | UBS | Buy |
| 2023-03-09 | ダウングレード | Citigroup | Buy → Neutral |
| 2023-01-05 | 開始されました | Scotiabank | Sector Outperform |
| 2022-11-01 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-10-19 | 開始されました | Craig Hallum | Buy |
| 2022-10-06 | 開始されました | Stephens | Overweight |
| 2022-08-25 | 開始されました | Credit Suisse | Outperform |
| 2022-06-03 | 開始されました | Piper Sandler | Overweight |
| 2022-04-28 | 再開されました | BTIG Research | Buy |
| 2022-02-24 | 繰り返されました | Canaccord Genuity | Buy |
| 2022-02-24 | 繰り返されました | Citigroup | Buy |
| 2022-02-24 | 繰り返されました | Cowen | Outperform |
| 2022-02-24 | 繰り返されました | Morgan Stanley | Overweight |
| 2022-02-24 | 繰り返されました | SVB Leerink | Outperform |
| 2022-02-24 | 繰り返されました | Stifel | Buy |
| 2022-02-24 | 繰り返されました | Wells Fargo | Overweight |
| 2021-10-15 | 再開されました | Cowen | Outperform |
| 2021-06-15 | 開始されました | Raymond James | Mkt Perform |
| 2021-06-03 | 開始されました | Goldman | Buy |
| 2021-05-25 | 開始されました | Wells Fargo | Overweight |
| 2021-01-11 | 開始されました | Stifel | Buy |
| 2020-09-09 | 開始されました | Morgan Stanley | Overweight |
| 2020-06-12 | 開始されました | BTIG Research | Buy |
| 2020-02-21 | 開始されました | Guggenheim | Buy |
| 2020-01-07 | 開始されました | Citigroup | Buy |
| 2019-08-07 | 繰り返されました | Canaccord Genuity | Buy |
| 2019-04-16 | 開始されました | Canaccord Genuity | Buy |
| 2019-04-10 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2019-02-28 | 繰り返されました | BofA/Merrill | Neutral |
| 2018-10-29 | 開始されました | BofA/Merrill | Neutral |
| 2018-10-29 | 開始されました | JP Morgan | Overweight |
| 2018-10-29 | 開始されました | William Blair | Outperform |
すべてを表示
Guardant Health Inc (GH) 最新ニュース
Guardant Health (GH) partners with Manulife to launch Shield multi-cancer detection test in Asia - MSN
Guardant Health Ignites 5.6% Surge: A Volatile Breakout or a Trap for the Unwary? - Bitget
Verana and Guardant’s RWE Stack Aims to Solve Precision Oncology’s Data Challenges—Driving Growth Through Recurring Revenue and Broader Data Collections - Bitget
Verana Health and Guardant Health Partner to Advance Precision Medicine with Real-World Data - PR Newswire
Guardant Health Manulife Shield Partnership Highlights Asia Growth And Valuation Gap - Yahoo Finance
GH Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Multiple analysts lift Guardant Health, Inc. (GH) targets on screening and data growth - MSN
Insiders Shake Up Guardant, Ovintiv, Redwire, Builders FirstSource, Permian - TipRanks
Why Guardant Health’s (GH) 2026 screening story reinforced Piper Sandler’s bullish view - MSN
Guardant Health (GH) Partners With Manulife to Launch Shield Multi-Cancer Detection Test in Asia - Insider Monkey
Guardant Health to present 28 abstracts on multiomic cancer research at AACR26 - Traders Union
Guardant Health, Inc. $GH Shares Sold by Polar Asset Management Partners Inc. - MarketBeat
GH Stock Price, Quote & Chart | GUARDANT HEALTH INC (NASDAQ:GH) - ChartMill
Insider Sell: Musa Tariq Sells Shares of Guardant Health Inc (GH) - GuruFocus
Guardant Health (GH) director Tariq Musa sells $30,655 in stock By Investing.com - Investing.com Australia
Insider Selling: Guardant Health (NASDAQ:GH) Director Sells 348 Shares of Stock - MarketBeat
Guardant Health (GH) director Tariq Musa sells $30,655 in stock - Investing.com
Guardant Health (NASDAQ: GH) director sells 348 company shares - Stock Titan
3 Reasons to Steer Clear of GH and One Alternative Stock Worth Buying - Bitget
Guardant Health Stock Analysis: Price Rise vs. Financial Risks | 2026News and Statistics - IndexBox
3 Reasons to Avoid GH and 1 Stock to Buy Instead - Yahoo Finance
15 Most Promising Stocks Under $100 to Buy - Insider Monkey
(GH) Risk Channels and Responsive Allocation - Stock Traders Daily
Cathie Wood’s ARK sells Guardant Health stock, buys Arcturus Therapeutics - Investing.com
Director at Guardant Health (GH) receives 232 shares via RSUs - Stock Titan
Guardant Health (NASDAQ: GH) Form 144 shows proposed insider sale of shares - Stock Titan
Guardant Health launches multi-cancer blood test in Asia through Manulife partnership - Mugglehead Investment Magazine
Guardant Health to Present 28 Abstracts Highlighting Advances in Tumor Typing, Therapy Selection and Expanded Utility of Multiomic Tissue and Liquid Biopsy Testing at AACR 2026 - BioSpace
Guardant Health acquires MetaSight amid positive 2026 financial outlook - MSN
Why Guardant Health’s (GH) 2026 Screening Story Reinforced Piper Sandler’s Bullish View - Insider Monkey
Guardant Health (GH) Co-CEO logs RSU grants, tax withholding and trust share transfer - Stock Titan
Guardant Health (GH) Co-CEO receives RSUs and shifts shares to trust - Stock Titan
Guardant Health (NASDAQ:GH) CFO Sells $261,120.00 in Stock - MarketBeat
Guardant Health launches Shield Multi-Cancer Detection Test in APAC market - BioSpectrum Asia
Guardant Health (GH) director acquires 249 shares via RSU vesting - Stock Titan
Guardant Health (NASDAQ: GH) CLO gains stock through RSU vesting - Stock Titan
Guardant Health (GH) CIO exercises RSUs and PBRSUs; 6,839 shares withheld for taxes - Stock Titan
Guardant Health (GH) CCO gains shares through RSU vesting and tax withholding - Stock Titan
Guardant Health (GH) CMO exercises RSUs; shares withheld to cover taxes - Stock Titan
Guardant Health (GH) CTO exercises 10,714 PSUs; 5,759 shares withheld for taxes - Stock Titan
Guardant Health (GH) CFO sells shares and reports RSU vesting - Stock Titan
Survey Supports Blood Tests for Colorectal Cancer Screening - Cure Today
Here’s Why Artisan Small Cap Fund Bets on Guardant Health (GH) - Insider Monkey
Oncology Molecular Diagnostics Market Growth 2026 | NGS, PCR - openPR.com
Singapore's Guardant Health launches Shield Multi-Cancer Detection (MCD) Test in APAC market - BioSpectrum Asia
Guardant Health Touts Quest Deal for Shield, Guardant360 Growth and FDA Milestones at Leerink Conference - MarketBeat
Algert Global LLC Raises Stock Holdings in Guardant Health, Inc. $GH - MarketBeat
Guardant Health Touts Hypergrowth in Guardant360, Reveal MRD and Shield CRC at Barclays Conference - MarketBeat
[144] Guardant Health, Inc. SEC Filing - Stock Titan
Guardant Health, Harris Poll Survey Shows 92% of Eligible Americans Believe Colorectal Cancer Blood Tests Should be Accessible and Covered - National Today
Guardant Health, Inc. $GH Shares Bought by Iron Triangle Partners LP - MarketBeat
Guardant Health Inc (GH) 財務データ
収益
当期純利益
現金流量
EPS
0.19%
0.04%
大文字化:
|
ボリューム (24 時間):